Neuroendocrine Tumors (NETs) Market Outlook

Thelansis’s “Neuroendocrine Tumors (NETs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neuroendocrine Tumors treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Neuroendocrine Tumors (NETs) Overview

Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms arising from secretory cells of the diffuse neuroendocrine system, occurring most commonly in the gastroenteropancreatic tract and lungs, characterised by variable hormonal secretory activity and somatostatin receptor overexpression. Well-differentiated NETs are graded G1 through G3 by Ki-67 proliferative index, while poorly differentiated neuroendocrine carcinomas represent a distinct aggressive entity. Functioning tumors produce hormonal syndromes including carcinoid syndrome, insulinoma, and gastrinoma, while non-functioning tumors present incidentally or with mass-effect symptoms. Diagnosis integrates specific hormonal assays, DOTATATE PET-CT for superior lesion detection and staging, and emerging mRNA-based blood assays including NETest; chromogranin A is increasingly de-emphasised given poor specificity, frequent false positivity with proton pump inhibitor use, and limited monitoring utility. Surgical resection remains the cornerstone of curative intent. Somatostatin analogues octreotide and lanreotide provide antiproliferative and antisecretory benefits. Lutetium-177 DOTATATE, supported by NETTER-2 trial data, is now established as first-line standard of care for advanced, high-burden somatostatin receptor-positive Grade 2 and Grade 3 GEP-NETs, representing a fundamental repositioning from later-line therapy. Everolimus and sunitinib address pancreatic NETs specifically, while telotristat ethyl controls refractory carcinoid syndrome diarrhoea. Prognosis varies with grade and disease extent; multidisciplinary management and patient-centred symptom control are integral to optimising outcomes.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)